UNFI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
United Natural Foods Inc (UNFI) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has positive momentum and bullish technical indicators, the company's financial performance in the latest quarter shows significant declines in revenue, net income, and EPS, which raises concerns about its long-term growth potential. Additionally, there are no strong proprietary trading signals or significant catalysts to justify immediate action.
The stock is currently in a bullish trend with MACD positively expanding, RSI indicating overbought conditions at 80.467, and moving averages showing a bullish crossover (SMA_5 > SMA_20 > SMA_200). The pre-market price is $45.92, nearing the first resistance level of $45.844, with a pivot at $42.456. However, the overbought RSI suggests a potential short-term pullback.
Analysts have upgraded the stock recently, with Wells Fargo raising the price target to $56 and highlighting the company's turnaround progress and growth potential in wellness and Amazon-related opportunities.
The stock has reached a record high, reflecting positive sentiment and momentum.
Gross margin increased by 0.76% YoY, indicating some operational improvements.
Financial performance in Q2 2026 shows significant declines: revenue dropped by -2.59% YoY, net income fell by -766.67% YoY, and EPS declined by -740.00% YoY.
RSI indicates overbought conditions, suggesting the stock may face short-term resistance.
No significant hedge fund or insider trading activity, and no recent congress trading data available.
In Q2 2026, revenue decreased to $7.947 billion (-2.59% YoY), net income dropped significantly to $20 million (-766.67% YoY), and EPS fell to $0.32 (-740.00% YoY). However, gross margin improved slightly to 13.24% (+0.76% YoY), reflecting some operational efficiency.
Analyst sentiment is mixed but leaning positive. Wells Fargo upgraded the stock to Overweight with a price target of $56, citing turnaround progress and growth in wellness. Other analysts have raised price targets but maintain Neutral or Hold ratings, reflecting cautious optimism. The average price target range is between $38 and $56.
